The review presents an organized discussion of some immunomodulators, i.e., sulforaphane, sunitinib, sorafenib, dasatinib, metformin, and IL-23 and IL-15 aiding CAR T-cell therapy specifically in the mitigation of cancer. Here, IL37 is linked to cancer.